Prescription drug expenditure increasing in USA

Prescription drug expenditure increasing in USA PharmacoEconomics & Outcomes News 804, p27 - 2 Jun 2018 Prescription drug expenditure increasing in USA Prescription drug expenditure in USA increased in 2017 and is projected to increase further in 2018, according to findings of a study published in American Journal of Health-System Pharmacy. Data from the IQVIA National Sales Perspectives database were used to assess prescription drug expenditure (costs of purchases from drug companies) in USA in 2017. Variables with a potential impact on prescription drug expenditure in hospitals and clinics in 2018, including new drug approvals and drug patent expiries, were reviewed, and prescription drug expenditure in 2018 was projected based on quantitative analyses and expert opinion. Total expenditure on prescription drugs in the US increased by 1.7% between 2016 and 2017, to 455.9 billion. Overall, the drugs with the highest expenditure were adalimumab ($17.1 billion), insulin glargine ($9.4 billion) and etanercept ($8.8 billion). Prescription expenditure decreased by 0.7% in 2017 versus 2016 in nonfederal hospitals, to $34.2 billion (primarily due to lower utilisation), but increased by 10.9% in clinics, to $70.8 billion. In 2017, the drugs with the highest expenditure in clinics were infliximab ($3.7 billion), pegfilgrastim (3.2 billion) and rituximab ($2.8 billion), while the drugs with the highest expenditure in nonfederal hospitals were rituximab, infliximab, alteplase, immune globulin and natalizumab. Total prescription drug expenditure in 2018 was projected to increase by between 3% and 5% overall, between 11% and 13.0% in clinics, and up to 2% in hospitals. "Health-system pharmacy leaders should carefully examine their own local drug utilization patterns to determine their own organization’s anticipated spending in 2018," said the authors. Schumock GT, et al. National trends in prescription drug expenditures and projections for 2018. American Journal of Health-System Pharmacy : 10 May 2018. Available from: URL: http://doi.org/10.2146/ajhp180138 803321890 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Prescription drug expenditure increasing in USA

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/prescription-drug-expenditure-increasing-in-usa-WgEdnfCroE
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-018-4991-2
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 804, p27 - 2 Jun 2018 Prescription drug expenditure increasing in USA Prescription drug expenditure in USA increased in 2017 and is projected to increase further in 2018, according to findings of a study published in American Journal of Health-System Pharmacy. Data from the IQVIA National Sales Perspectives database were used to assess prescription drug expenditure (costs of purchases from drug companies) in USA in 2017. Variables with a potential impact on prescription drug expenditure in hospitals and clinics in 2018, including new drug approvals and drug patent expiries, were reviewed, and prescription drug expenditure in 2018 was projected based on quantitative analyses and expert opinion. Total expenditure on prescription drugs in the US increased by 1.7% between 2016 and 2017, to 455.9 billion. Overall, the drugs with the highest expenditure were adalimumab ($17.1 billion), insulin glargine ($9.4 billion) and etanercept ($8.8 billion). Prescription expenditure decreased by 0.7% in 2017 versus 2016 in nonfederal hospitals, to $34.2 billion (primarily due to lower utilisation), but increased by 10.9% in clinics, to $70.8 billion. In 2017, the drugs with the highest expenditure in clinics were infliximab ($3.7 billion), pegfilgrastim (3.2 billion) and rituximab ($2.8 billion), while the drugs with the highest expenditure in nonfederal hospitals were rituximab, infliximab, alteplase, immune globulin and natalizumab. Total prescription drug expenditure in 2018 was projected to increase by between 3% and 5% overall, between 11% and 13.0% in clinics, and up to 2% in hospitals. "Health-system pharmacy leaders should carefully examine their own local drug utilization patterns to determine their own organization’s anticipated spending in 2018," said the authors. Schumock GT, et al. National trends in prescription drug expenditures and projections for 2018. American Journal of Health-System Pharmacy : 10 May 2018. Available from: URL: http://doi.org/10.2146/ajhp180138 803321890 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off